Clinical Trials in Boston

Showing 7941-7960 of 13,548 trials

Relational Agent for Alcohol Screening and Treatment

NCT02030288

This project will involve the development and initial evaluation of a promising computer-based intervention to improve the primary care management of risky alcohol use among Veterans. The intervention uses a Relational Agent, an on-screen "person" that establishes a relationship with the Veteran to promote positive health behaviors. This study will determine how Veterans interact with this system, how it can be tailored to Veterans' preferences, and its potential effect on risky drinking. If ultimately proven effective, the Relational Agent will have several impacts on Veterans and their health care, including: * (1) lower rates of risky drinking in Veterans * (2) improved rates of brief counseling for Veterans with excessive alcohol use * (3) increased proportion of Veterans referred to Mental Health for alcohol disorders * (4) improved care for Veterans with low levels of health literacy. This study directly supports Secretary Shinseki's Transformational Initiative to employ state-of-the-art information technology to improve quality and access of Veterans' health care.

Unhealthy Alcohol UseAlcohol Use DisorderAlcohol Disorders

VA Office of Research and Development178 participantsStarted Feb 2015

Boston, Massachusetts, United States

COMPLETEDPhase 1< 1 mile

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

NCT02759016

Intravenous BI 836826 in combination with ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) patients who have been pre-treated with at least one prior line of systemic therapy, and who are eligible for treatment with ibrutinib. Objectives of the trial are to determine the recommended Phase 2 dose of BI 836826, and to document the safety and tolerability of BI 836826 when given in combination with ibrutinib

Leukemia, Lymphocytic, Chronic, B-Cell

Boehringer Ingelheim7 participantsStarted Jun 2016

Duarte, California, United States • Boston, Massachusetts, United States • Portland, Oregon, United States

Relational Agent for Alcohol Screening and Treatment

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Find Trials by Condition in Boston

Comparison of Post Tooth Extraction Healing Using Different Xenograft Materials

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses

EVOLVE Short DAPT Study

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia

Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters

Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Dental Hypersensitivity

Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias